Member
Keylicon Biosciences
Keylicon Biosciences is developing the next generation of self-amplifying RNA (saRNA) to deliver low-dose, durable vaccines and therapeutics. Our platform produces multivalent vaccines that generate long-lasting immunity from low doses, and can express therapeutic proteins directly within diseased tissues, such as tumors, with high specificity following systemic administration.
Industries
Biotechnology
Nr. of Employees
small (1-50)
Expertise Areas
- RNA therapeutics
- RNA vaccines
- Immunotherapy
Key Technologies
- Self-amplifying RNA
- Lipid nanoparticles